ライフサイエンスコーパス: vitreal

1 Brief bright flashes were used to elicit vitreal a- and b-waves.

2 Vitreal and intraretinal ERGs were recorded from eight d

3 Vitreal aspirations and grading of vitreal inflammatory

4 Vitreal aspirations demonstrated no growth by 5 days fro

5 Vitreal band formation was significantly higher in ABLC-

6 se alterations can be attributed to elevated vitreal bFGF in conjunction with osmotic stress and asso

7 e this disease, VEGF's major contribution to vitreal bioactivity occurred via platelet-derived growth

8 s, intravitreal injection, choroidal retinal vitreal biopsy, and human immunodeficiency virus infecti

9 is highly concentrated at the endfeet at the vitreal border and to processes enveloping blood vessels

10 C migration from the ventricular zone to the vitreal border was significantly inhibited, suggesting t

11 noblastoma cell lines were injected into the vitreal cavities of immunodeficient mice.

12 2 microg/d) from a capsule sutured into the vitreal cavity after prior cryopexy.

13 r tumors that were initially confined to the vitreal cavity.

14 esulting from significant lengthening of the vitreal chamber of the eye.

15 +/- 1.8 diopters) with significantly shorter vitreal chambers.

16 an that of the IRDye800CW alone, whereas the vitreal clearance (CL) and volume of distribution (V(ss)

17 at collagen XVIII is important for anchoring vitreal collagen fibrils to the inner limiting membrane.

18 rvival) is roughly 1000-fold higher than the vitreal concentration and 20-fold higher than the sclera

19 At the vitreal concentration of 41 muM, caspofungin reduced the

20 rvet monkeys (Chlorocebus sabaeus; estimated vitreal concentration: 1 mM, n = 3; 2 mM, n = 1; 10 mM,

21 e left eyes of male C57BL/6 mice, with final vitreal concentrations corresponding to 0.41, 1.2, 2.5,

22 Moreover, vitreal concentrations determined in situ were >3 orders

23 Mice injected with caspofungin at vitreal concentrations from 0.41 to 4.1 muM did not have

24 Caspofungin is a safe antifungal agent at vitreal concentrations of 0.41 to 4.1 muM in mice and co

25 Vitreal concentrations of CVX-4164 determined in situ de

26 Vitreal cytokine secretion was measured by ELISA and mul

27 The hindrance of retinal and vitreal drug delivery by the choroid-RPE in pigmented ra

28 Transscleral retinal and vitreal drug delivery of lipophilic celecoxib is signifi

29 roteins by cellular receptor proteins on the vitreal endfeet of the retinal neuroepithelial cells.

30 We sought to identify vitreal factors required for experimental PVR and to est

31 nmf223, which is characterized clinically by vitreal fibroplasia and vessel tortuosity.

32 Here, we show that vitreal fluids from patients with proliferative diabetic

33 Chronic BRI treatment had no effect on vitreal glutamate concentrations in diabetic animals but

34 Vitreal glutamate concentrations were not elevated in ey

35 ntly elevated vitreoretinal VEGF expression, vitreal glutamate concentrations, and BRB leakage compar

36 The mean level (+/- SD) of vitreal glutamate in the eight untreated monkeys was 5.0

37 is in contradiction to previous reports that vitreal glutamate increases to toxic levels and probably

38 glaucomatous eyes, the mean concentration of vitreal glutamate was 5.7 +/- 2.6 microM, which was not

39 ore whether a chronic, low-dose elevation in vitreal glutamate was toxic to retinal ganglion cells an

40 Mean levels of vitreal glutamate were determined for the treated and co

41 Vitreoretinal VEGF protein, vitreal glutamate, and BRB breakdown were then measured.

42 of expression of the transporter, increased vitreal glutamate, and was toxic to ganglion cells.

43 combination therapy encompassing a subset of vitreal growth factors and cytokines is a potential appr

44 factors (PDGFs) are present in the vitreous, vitreal growth factors outside of the PDGF family activa

45 Vitreal growth factors outside the PDGF family modestly

46 promotes experimental PVR driven by multiple vitreal growth factors outside the PDGF family.

47 an be activated by a much larger spectrum of vitreal growth factors than previously appreciated.

48 Vitritis was graded by the degree of vitreal haze.

49 a scenario that leads to retinal detachment, vitreal hemorrhages, neuronal apoptosis, and impairment

50 Vitreal hemorrhages, orbital fat hemorrhages, and macula

51 Vitreal IL-1beta, IL-6, and TNF-alpha were upregulated b

52 Vitreal inflammation was greater in eyes treated with L-

53 Vitreal aspirations and grading of vitreal inflammatory reaction were done regularly until

54 In vivo vitreal injection of the gliotoxin fluorocitrate (150 mu

55 Primates undergoing vitreal injection with the ND4 test article and followed

56 ids such as triamcinolone and steroid-loaded vitreal inserts and implants have been found to be effec

57 or chamber depth (ACD), lens thickness (LT), vitreal length (VL), axial length (AL), lens position an

58 (2) noninvasively and evaluated effects from vitreal macromolecules, temperature gradients, and ambie

59 nner limiting membrane and separation of the vitreal matrix from the inner limiting membrane in mutan

60 Axial measurements of SD-OCT also revealed vitreal morphology that was not readily visualized by hi

61 Consequently, retinal and vitreal neovascularization occurs, a scenario that leads

62 eyes treated with ABLC showed development of vitreal opacities than developed in eyes treated with am

63 thalmoscopy revealed unilateral or bilateral vitreal opacities, fibrous retrolental tissue, and retin

64 The oxygenation group underwent vitreal oxygenation for 30 minutes using intravitreal el

65 In severe total ocular ischemia, anterior vitreal oxygenation supplies enough oxygen to penetrate

66 However, the retinal (P = 0.001) and vitreal (P = 0.001) AUCs of celecoxib in the treated eye

67 The vitreal P70 extracts contained 49- and 53-kDa gelatinoly

68 the altered extracellular environment in the vitreal part of the retina, resulting in the retraction

69 Neutralizing vitreal PDGFs did not effectively attenuate PVR, even th

70 These observations beg the question of why vitreal PDGFs fail to activate PDGFRalpha.

71 s, temperature gradients, and ambient air on vitreal Po(2) values.

72 If uncorrected, vitreal Po(2) would be significantly overestimated (P <

73 rs was high for both the inner border of the vitreal pocket (kappa, 0.86; P < .001) and the outer cho

74 nt to conventional SD OCT in visualizing the vitreal pocket (P = .445 for normal eyes, P = .162 for e

75 robiotin-injected DA cells proved that their vitreal processes were situated in stratum S3 of the IPL

76 Limited proteolysis showed that the vitreal protein has a protease-sensitive region at its s

77 regression of the new vascular tufts on the vitreal side with normal organization and thickness of t

78 In humans, vitreal stromal cell-derived factor-1 (SDF-1) concentrat

79 cells, and ER-mitochondrial contacts at the vitreal surface of the end-foot.

80 0-immunoreactive puncta were confined to the vitreal surface of the retina and colocalized with GFAP-

81 ndfeet of the neuroepithelial cells from the vitreal surface of the retina, the formation of a disorg

82 ir perikarya translocate rapidly towards the vitreal surface of the retina.

83 unction to anchor the radial end feet to the vitreal surface of the retina.

84 ation), donor cells appeared attached to the vitreal surface of the retina.

85 n approximately 10-microm-thick layer at the vitreal surface of the retina.

86 stimulating electrode was positioned at the vitreal surface of the slice.

87 in the inner plexiform layer, and along the vitreal surface, but it was only found in blood vessels

88 present at stage 15 (S15) in cells near the vitreal surface.

89 The vitreal surfaces of the large retinal vessels were cover

90 itreal hemorrhage, of whom 9 (4.1%) required vitreal surgery.

91 ary retinal dysplasia, delayed regression of vitreal vasculature, and retarded apoptotic kinetics of

92 (group 1) had significantly lower levels of vitreal VEGF-A (141.11 +/- 61.89 pg/mL) when compared wi

93 Primary outcome was vitreal VEGF-A levels (at the time of anti-VEGF injectio

94 -VEGF treatment is associated with decreased vitreal VEGF-A levels in wet AMD patients.

95 crog versus 0.5 microg), when differences in vitreal volume are considered, the effective dose is sim

96 ive dose is similar (0.01 microg BDNF/microl vitreal volume).